In a metaanalysis of randomized clinical trials (1060 patients) with COVID-19 treated with CP versus control, it was concluded that treatment with CP compared with placebo or standard of care was not significantly associated with a decrease in all-cause mortality or with any benefit for other clinical outcomes [13]. The gene discussed is CP; the disease is COVID-19.